Clinical Trial

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-01-19; most recent amendment 2024-10-08.
Status change: Recruiting → Active, Not Recruiting 2024-10-08
Status change: Not Yet Recruiting → Recruiting 2022-02-08
Trial Details
NCT Number NCT05215574
Lead Sponsor NGM Biopharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC
Conditions Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer +8 more
Enrollment 130 participants
Start Date 2022-03-31
Primary Completion 2025-07 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2024-10-10